Barostim plus GDMT provides significant and meaningful improvements for heart failure patients beyond GDMT alone
HR 0.662 (95% CI 0.435, 1.007)
Patients in the Barostim arm had a 34% reduction in all-cause death or the use of LVAD or heart transplant at > 4 years follow-up
HR 1.26 (95% CI 1.02, 1.58)
26% more patients in the Barostim arm had better outcomes as evaluated by hierarchical composite of CV mortality, LVAD/transplant, HF hospitalization and quality of life
Freedom from major adverse neurological or cardiovascular system or procedure-related event rate in the Barostim arm
1. Instructions for Use 900133-001 Rev. D available at www.cvrx.com/ifu; 2. Gremeaux V, et al. Arch Phys Med Rehabil. 2011;92(4):611-619.; 3. Rector TS, et al. J Card Fail. 1995;1(3):201-216;